Sun Pharmaceutical Industries Limited announced that its Chairman and member of the Board, Mr. Israel Makov, will retire from the company upon the completion of his current term post Sun Pharma's Annual General Meeting on August 29, 2022, after having led the organisation for 10 years. He was appointed a Board member and the Chairman in 2012. Under his leadership, Sun Pharma transformed from a USD 1.7 billion organisation focusing on India and the US into the world's fourth large specialty generic pharmaceutical company operating across 100+ markets with a turnover of over USD 5 billion.

Leading the company's global expansion, he guided the acquisition of Ranbaxy in 2014, making Sun Pharma the leader in the Indian pharmaceutical market and a strong player globally. Mr. Makov helped steer the company to pursue its strategy of building a global pipeline of specialty products.